Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: What needs to be explored?

Annals of Gastroenterology

Volumn 30, Issue 4, 2017, Pages 380-392

  Ierardi, Enzo ^a   Losurdo, Giuseppe ^a   Iannone, Andrea ^a   Piscitelli, Domenico ^a   Amoruso, Annacinzia ^a   Barone, Michele ^a   Principi, Mariabeatrice ^a   Pisani, Antonio ^a   Di Leo, Alfredo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Celiac disease; Duodenal lymphocytosis; Gluten sensitivity; Gluten free diet; Intraepithelial lymphocytes; Microscopic enteritis

Indexed keywords

ACETYLSALICYLIC ACID; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; INDOMETACIN; LAXATIVE; MERCAPTOPURINE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; PREBIOTIC AGENT; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; SPASMOLYTIC AGENT; STEROID;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE ENTEROPATHY; BACTERIAL INFECTION; CELIAC DISEASE; CLINICAL FEATURE; DERMATITIS HERPETIFORMIS; DUODENITIS; ENTERITIS; ENTEROPATHY; FOOD ALLERGY; GIARDIASIS; GLUTEN FREE DIET; HELICOBACTER INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNITY; IMMUNOGLOBULIN DEFICIENCY; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; IRRITABLE COLON; LYMPHOCYTE; LYMPHOCYTIC DUODENITIS; LYMPHOCYTOSIS; MICROSCOPIC ENTERITIS; MONCELIAC GLUTEN SENSITIVITY; NONHUMAN; NUTRITIONAL INTOLERANCE; REVIEW; RISK FACTOR; SEROLOGY; WHEAT ALLERGY;

EID: 85021400055     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: 10.20524/aog.2017.0165     Document Type: Review

References (155)

1. Hammer ST, Greenson JK. The clinical significance of duodenal lymphocytosis with normal villus architecture. Arch Pathol Lab Med 2013;137:1216-1219.
2. Rostami K, Aldulaimi D, Holmes G, et al. Microscopic enteritis:Bucharest consensus. World J Gastroenterol 2015;21:2593-2604.
3. Rostami K, Villanacci V. Microscopic enteritis: novel prospect in coeliac disease clinical and immuno-histogenesis. Evolution in diagnostic and treatment strategies. Dig Liver Dis 2009;41:245-252.
4. Robert ME. Gluten sensitive enteropathy and other causes of small intestinal lymphocytosis. Semin Diagn Pathol 2005;22:284-294.
5. Dickson BC, Streutker CJ, Chetty R. Coeliac disease: an update for pathologists. J Clin Pathol 2006;59:1008-1016.
6. Crowe PT, Marsh MN. Morphometric analysis of intestinal mucosa. VI-Principles in enumerating intra-epithelial lymphocytes. Virchows Arch 1994;424:301-306.
7. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology 1992;102:330-354.
8. Galli G, Purchiaroni F, Lahner E, et al. Time trend occurrence of duodenal intraepithelial lymphocytosis and celiac disease in an open access endoscopic population. United European Gastroenterol J 2016 in press.
9. Kakar S, Nehra V, Murray JA, Dayharsh GA, Burgart LJ. Significance of intraepithelial lymphocytosis in small bowel biopsy samples with normal mucosal architecture. Am J Gastroenterol 2003;98:2027-2033.
10. Mahadeva S, Wyatt JI, Howdle PD. Is a raised intraepithelial lymphocyte count with normal duodenal villous architecture clinically relevant? J Clin Pathol 2002;55:424-428.
11. Shmidt E, Smyrk TC, Faubion WA, Oxentenko AS. Duodenal intraepithelial lymphocytosis with normal villous architecture in pediatric patients: Mayo Clinic experience, 2000-2009. J Pediatr Gastroenterol Nutr 2013;56:51-55.
12. Shmidt E, Smyrk TC, Boswell CL, Enders FT, Oxentenko AS. Increasing duodenal intraepithelial lymphocytosis found at upper endoscopy: time trends and associations. Gastrointest Endosc 2014;80:105-111.
13. Abadie V, Discepolo V, Jabri B. Intraepithelial lymphocytes in celiac disease immunopathology. Semin Immunopathol 2012;34:551-566.
14. Forsberg G, Hernell O, Hammarström S, Hammarström ML. Concomitant increase of IL-10 and pro-inflammatory cytokines in intraepithelial lymphocyte subsets in celiac disease. Int Immunol 2007;19:993-1001.
15. Lundqvist C, Melgar S, Yeung MM, Hammarström S, Hammarström ML. Intraepithelial lymphocytes in human gut have lytic potential and a cytokine profile that suggest T helper 1 and cytotoxic functions. J Immunol 1996;157:1926-1934.
16. Ogata M, Ota Y, Matsutani T, Nanno M, Suzuki R, Itoh T. Granzyme B-dependent and perforin-independent DNA fragmentation in intestinal epithelial cells induced by anti-CD3 mAb-activated intra-epithelial lymphocytes. Cell Tissue Res 2013;352:287-300.
17. Camarca A, Del Mastro A, Gianfrani C. Repertoire of gluten peptides active in celiac disease patients: perspectives for translational therapeutic applications. Endocr Metab Immune Disord Drug Targets 2012;12:207-219.
18. Gianfrani C, Auricchio S, Troncone R. Adaptive and innate immune responses in celiac disease. Immunol Lett 2005;99:141-145.
19. Jiang W, Wang X, Zeng B, et al. Recognition of gut microbiota by NOD2 is essential for the homeostasis of intestinal intraepithelial lymphocytes. J Exp Med 2013;210:2465-2476.
20. Fasano A, Catassi C. Clinical practice. Celiac disease. N Engl J Med 2012;367:2419-2426.
21. Zanini B, Caselani F, Magni A, et al. Celiac disease with mild enteropathy is not mild disease. Clin Gastroenterol Hepatol 2013;11:253-258.
22. Zanini B, Lanzarotto F, Villanacci V, Carabellese N, Ricci C, Lanzini A. Clinical expression of lymphocytic duodenosis in “mild enteropathy” celiac disease and in functional gastrointestinal syndromes. Scand J Gastroenterol 2014;49:794-800.
23. Tursi A, Brandimarte G, Giorgetti G, Gigliobianco A, Lombardi D, Gasbarrini G. Low prevalence of antigliadin and anti-endomysium antibodies in subclinical/silent celiac disease. Am J Gastroenterol 2001;96:1507-1510.
24. Volta U, Caio G, Boschetti E, et al. Seronegative celiac disease:Shedding light on an obscure clinical entity. Dig Liver Dis 2016;48:1018-1022.
25. Ierardi E, Losurdo G, Piscitelli D, et al. Seronegative celiac disease:where is the specific setting? Gastroenterol Hepatol Bed Bench 2015;8:110-116.
26. Auricchio R, Tosco A, Piccolo E, et al. Potential celiac children:9-year follow-up on a gluten-containing diet. Am J Gastroenterol 2014;109:913-921.
27. Ierardi E, Amoruso A, Giorgio F, et al. Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at Marsh 1 and 0 stages. Saudi J Gastroenterol 2015;21:379-385.
28. Leffler D, Vanga R, Mukherjee R. Mild enteropathy celiac disease: a wolf in sheep’s clothing? Clin Gastroenterol Hepatol 2013;11:259-261.
29. Fasano A, Sapone A, Zevallos V, Schuppan D. Nonceliac gluten sensitivity. Gastroenterology 2015;148:1195-1204.
30. Volta U, De Giorgio R. New understanding of gluten sensitivity. Nat Rev Gastroenterol Hepatol 2012;9:295-299.
31. Sapone A, Lammers KM, Casolaro V, et al. Divergence of gut permeability and mucosal immune gene expression in two glutenassociated conditions: celiac disease and gluten sensitivity. BMC Med 2011;9:23.
32. Caio G, Riegler G, Patturelli M, Facchiano A, DE Magistris L, Sapone A. Pathophysiology of non-celiac gluten sensitivity: where are we now? Minerva Gastroenterol Dietol 2017;63:16-21.
33. Volta U, Tovoli F, Cicola R, et al. Serological tests in gluten sensitivity (nonceliac gluten intolerance). J Clin Gastroenterol 2012;46:680-685.
34. De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut 2016;65:169-178.
35. Zevallos VF, Raker V, Tenzer S, et al. Nutritional wheat amylasetrypsin inhibitors promote intestinal inflammation via activation of myeloid cells. Gastroenterology 2017;152:1100-1113.e12.
36. Carroccio A, Rini G, Mansueto P. Non-celiac wheat sensitivity is a more appropriate label than non-celiac gluten sensitivity. Gastroenterology 2014;146:320-321.
37. Aziz I, Lewis NR, Hadjivassiliou M, et al. A UK study assessing the population prevalence of self-reported gluten sensitivity and referral characteristics to secondary care. Eur J Gastroenterol Hepatol 2014;26:33-39.
38. Catassi C, Elli L, Bonaz B, et al. Diagnosis of non-celiac gluten sensitivity (NCGS): the Salerno experts’ criteria. Nutrients 2015;7:4966-4977.
39. Elli L, Tomba C, Branchi F, et al. Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: results from a multicenter randomized double-blind placebo-controlled gluten challenge. Nutrients 2016;8:84.
40. Francavilla R, Cristofori F, Castellaneta S, et al. Clinical, serologic, and histologic features of gluten sensitivity in children. J Pediatr 2014;164:463-467.e1.
41. Catassi C, Bai JC, Bonaz B, et al. Non-celiac gluten sensitivity:the new frontier of gluten related disorders. Nutrients 2013;5:3839-3853.
42. Villanacci V, Lanzini A, Lanzarotto F, Ricci C. Observations on the paper of Carroccio et al. “non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity”. Am J Gastroenterol 2013;108:619-620.
43. Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012;107:1898-1906.
44. Czaja-Bulsa G, Bulsa M. What do we know now about IgEmediated wheat allergy in children? Nutrients 2017;9. doi: 10.3390/ nu9010035.
45. Keet CA, Matsui EC, Dhillon G, Lenehan P, Paterakis M, Wood RA. The natural history of wheat allergy. Ann Allergy Asthma Immunol 2009;102:410-415.
46. Czaja-Bulsa G, Bulsa M. The natural history of IgE mediated wheat allergy in children with dominant gastrointestinal symptoms. Allergy Asthma Clin Immunol 2014;10:12.
47. Mansouri M, Pourpak Z, Mozafari H, Abdollah Gorji F, Shokouhi Shoormasti R. Follow-up of the wheat allergy in children; consequences and outgrowing the allergy. Iran J Allergy Asthma Immunol 2012;11:157-163.
48. Matsuo H, Dahlström J, Tanaka A, et al. Sensitivity and specificity of recombinant omega-5 gliadin-specific IgE measurement for the diagnosis of wheat-dependent exercise-induced anaphylaxis. Allergy 2008;63:233-236.
49. Carroccio A, Mansueto P, D’Alcamo A, Iacono G. Non-celiac wheat sensitivity as an allergic condition: personal experience and narrative review. Am J Gastroenterol 2013;108:1845-1852.
50. Salmi TT, Hervonen K, Kautiainen H, Collin P, Reunala T. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol 2011;165:354-359.
51. Rose C, Armbruster FP, Ruppert J, Igl BW, Zillikens D, Shimanovich I. Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol 2009;61:39-43.
52. Savilahti E, Ormälä T, Arato A, et al. Density of gamma/delta+ T cells in the jejunal epithelium of patients with coeliac disease and dermatitis herpetiformis is increased with age. Clin Exp Immunol 1997;109:464-467.
53. Vecchi M, Crosti L, Berti E, Agape D, Cerri A, De Franchis R. Increased jejunal intraepithelial lymphocytes bearing gamma/ delta T-cell receptor in dermatitis herpetiformis. Gastroenterology 1992;102:1499-1505.
54. Reunala T, Kosnai I, Karpati S, Kuitunen P, Török E, Savilahti E. Dermatitis herpetiformis: jejunal findings and skin response to gluten free diet. Arch Dis Child 1984;59:517-522.
55. Vitoria JC, Camarero C, Sojo A, Ruiz A, Rodriguez-Soriano J. Enteropathy related to fish, rice, and chicken. Arch Dis Child 1982;57:44-48.
56. Stern M, Dietrich R, Müller J. Small intestinal mucosa in coeliac disease and cow’s milk protein intolerance: morphometric and immunofluorescent studies. Eur J Pediatr 1982;139:101-105.
57. Pesce G, Pesce F, Fiorino N, et al. Intraepithelial gamma/deltapositive T lymphocytes and intestinal villous atrophy. Int Arch Allergy Immunol 1996;110:233-237.
58. Kokkonen J, Holm K, Karttunen TJ, Mäki M. Children with untreated food allergy express a relative increment in the density of duodenal gammadelta+ T cells. Scand J Gastroenterol 2000;35:1137-1142.
59. Gentile NM, Murray JA, Pardi DS. Autoimmune enteropathy: a review and update of clinical management. Curr Gastroenterol Rep 2012;14:380-385.
60. Marthinsen LM, Scott H, Ejderhamn J. Autoimmune enteropathy in Swedish children, 1985-2002: a call for strict diagnostic criteria. Scand J Gastroenterol 2008;43:1102-1107.
61. Masia R, Peyton S, Lauwers GY, Brown I. Gastrointestinal biopsy findings of autoimmune enteropathy: a review of 25 cases. Am J Surg Pathol 2014;38:1319-1329.
62. Diaz L, Hernandez-Oquet RE, Deshpande AR, Moshiree B. Upper Gastrointestinal involvement in Crohn disease: histopathologic and endoscopic findings. South Med J 2015;108:695-700.
63. Patterson ER, Shmidt E, Oxentenko AS, Enders FT, Smyrk TC. Normal villous architecture with increased intraepithelial lymphocytes: a duodenal manifestation of Crohn disease. Am J Clin Pathol 2015;143:445-450.
64. Vidali F, Di Sabatino A, Broglia F, et al. Increased CD8+ intraepithelial lymphocyte infiltration and reduced surface area to volume ratio in the duodenum of patients with ulcerative colitis. Scand J Gastroenterol 2010;45:684-689.
65. Kokkonen J, Arvonen M, Vähäsalo P, Karttunen TJ. Intestinal immune activation in juvenile idiopathic arthritis and connective tissue disease. Scand J Rheumatol 2007;36:386-389.
66. Casis B, Fernández-Vázquez I, Barnardos E, et al. Autoimmune enteropathy in an adult with autoimmune multisystemic involvement. Scand J Gastroenterol 2002;37:1012-1016.
67. Ning-Sheng L, Ruay-Sheng L, Kuo-Chih T. High frequency of unusual gastric/duodenal ulcers in patients with Behçet’s disease in Taiwan: a possible correlation of MHC molecules with the development of gastric/duodenal ulcers. Clin Rheumatol 2005;24:516-520.
68. Cindoruk M, Tuncer C, Dursun A, et al. Increased colonic intraepithelial lymphocytes in patients with Hashimoto’s thyroiditis. J Clin Gastroenterol 2002;34:237-239.
69. Michaëlsson G, Kraaz W, Hagforsen E, Pihl-Lundin I, Lööf L, Scheynius A. The skin and the gut in psoriasis: the number of mast cells and CD3+ lymphocytes is increased in non-involved skin and correlated to the number of intraepithelial lymphocytes and mast cells in the duodenum. Acta Derm Venereol 1997;77:343-346.
70. Rodrigo L, Hernández-Lahoz C, Fuentes D, Alvarez N, López-Vázquez A, González S. Prevalence of celiac disease in multiple sclerosis. BMC Neurol 2011;11:31.
71. Lebwohl B, Blaser MJ, Ludvigsson JF, et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol 2013;178:1721-1730.
72. Rosinach M, Esteve M, González C, et al. Lymphocytic duodenosis:aetiology and long-term response to specific treatment. Dig Liver Dis 2012;44:643-648.
73. Simondi D, Ribaldone DG, Bonagura GA, et al. Helicobacter pylori in celiac disease and in duodenal intraepithelial lymphocytosis:active protagonist or innocent bystander? Clin Res Hepatol Gastroenterol 2015;39:740-745.
74. Memeo L, Jhang J, Hibshoosh H, Green PH, Rotterdam H, Bhagat G. Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. Mod Pathol 2005;18:1134-1144.
75. Nahon S, Patey-Mariaud De Serre N, Lejeune O, et al. Duodenal intraepithelial lymphocytosis during Helicobacter pylori infection is reduced by antibiotic treatment. Histopathology 2006;48:417-423.
76. Guz-Mark A, Zevit N, Morgenstern S, Shamir R. Duodenal intraepithelial lymphocytosis is common in children without coeliac disease, and is not meaningfully influenced by Helicobacter pylori infection. Aliment Pharmacol Ther 2014;39:1314-1320.
77. Yoshida N, Granger DN, Evans DJ Jr, et al. Mechanisms involved in Helicobacter pylori-induced inflammation. Gastroenterology 1999;105:1431-1440.
78. Rostami-Nejad M, Javad Ehsani-Ardakani M, Assadzadeh H, et al. Pathological and clinical correlation between celiac disease and Helicobacter pylori infection; a review of controversial reports. Middle East J Dig Dis 2016;8:85-92.
79. Rostami Nejad M, Rostami K, Yamaoka Y, et al. Clinical and histological presentation of Helicobacter pylori and gluten related gastroenteropathy. Arch Iran Med 2011;14:115-118.
80. Cama VA, Mathison BA. Infections by intestinal coccidia and Giardia duodenalis. Clin Lab Med 2015;35:423-444.
81. Lewis DJ, Freedman AR. Giardia lamblia as an intestinal pathogen. Dig Dis 1992;10:102-111.
82. Santos RB, Fonseca LE Jr, Santana AT, Silva CA, Guedes JC. Clinical, endoscopic and histopathological profiles of parasitic duodenitis cases diagnosed by upper digestive endoscopy. Arq Gastroenterol 2011;48:225-230.
83. Ferguson A, McClure JP, Townley RR. Intraepithelial lymphocyte counts in small intestinal biopsies from children with diarrhoea. Acta Paediatr Scand 1976;65:541-546.
84. Brown IS, Bettington A, Bettington M, Rosty C. Tropical sprue: revisiting an underrecognized disease. Am J Surg Pathol 2014;38:666-672.
85. Riordan SM, McIver CJ, Wakefield D, Duncombe VM, Thomas MC, Bolin TD. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol 2001;96:494-500.
86. Santolaria S, Dominguez M, Alcedo J, et al. [Lymphocytic duodenosis: etiological study and clinical presentations]. Gastroenterol Hepatol 2013;36:565-573.
87. Losurdo G, Marra A, Shahini E, et al. Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooleddata analysis. Neurogastroenterol Motil 2017;29. doi: 10.1111/ nmo.13028.
88. Giorgio F, Principi M, Losurdo G, et al. Seronegative celiac disease and immunoglobulin deficiency: where to look in the submerged iceberg? Nutrients 2015;7:7486-7504.
89. Agarwal S, Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol 2013;11:1050-1063.
90. Brandtzaeg P. Update on mucosal immunoglobulin A in gastrointestinal disease. Curr Opin Gastroenterol 2010;26:554-563.
91. Wang N, Truedsson L, Elvin K, et al. Serological assessment for celiac disease in IgA deficient adults. PLoS One 2014;9:e93180.
92. Lenhardt A, Plebani A, Marchetti F, et al. Role of humantissue transglutaminase IgG and anti-gliadin IgG antibodies in the diagnosis of coeliac disease in patients with selective immunoglobulin A deficiency. Dig Liver Dis 2004;36:730-734.
93. Wang N, Shen N, Vyse TJ, et al. Selective IgA deficiency in autoimmune diseases. Mol Med 2011;17:1383-1396.
94. Abolhassani H, Sagvand BT, Shokuhfar T, Mirminachi B, Rezaei N, Aghamohammadi A. A review on guidelines for management and treatment of common variable immunodeficiency. Expert Rev Clin Immunol 2013;9:561-574.
95. Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem 1996;34:517-520.
96. Ohno T, Inaba M, Kuribayashi K, Masuda T, Kanoh T, Uchino H. Selective IgM deficiency in adults: phenotypically and functionally altered profiles of peripheral blood lymphocytes. Clin Exp Immunol 1987;68:630-637.
97. Hobbs JR, Hepner GW. Deficiency of M-globulin in coeliac disease. Lancet 1968;291:217-220.
98. Brown DL, Cooper AG, Hepner GW. IgM metabolism in coeliac disease. Lancet 1969;1:858-861.
99. Montenegro L, Piscitelli D, Giorgio F, et al. Reversal of IgM deficiency following a gluten-free diet in seronegative celiac disease. World J Gastroenterol 2014;20:17686-17689.
100. Lougaris V, Ravelli A, Villanacci V, et al. Gastrointestinal pathologic abnormalities in pediatric- and adult-onset common variable immunodeficiency. Dig Dis Sci 2015;60:2384-2389.
101. Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol 2010;105:2262-2275.
102. Luzi G, Zullo A, Iebba F, et al. Duodenal pathology and clinical-immunological implications in common variable immunodeficiency patients. Am J Gastroenterol 2003;98:118-121.
103. Biagi F, Bianchi PI, Zilli A, et al. The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: a clinical and histopathologic study. Am J Clin Pathol 2012;138:185-189.
104. Venhoff N, Emmerich F, Neagu M, et al. The role of HLA DQ2 and DQ8 in dissecting celiac-like disease in common variable immunodeficiency. J Clin Immunol 2013;33:909-916.
105. Licinio R, Principi M, Amoruso A, Piscitelli D, Ierardi E, Di Leo A. Celiac disease and common variable immunodeficiency: a familial inheritance? J Gastrointestin Liver Dis 2013;22:473.
106. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol 2013;19:1861-1876.
107. Lamarque D, Nhieu JT, Breban M, et al. Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic feature of ankylosing spondylitis. J Rheumatol 2003;30:2428-2436.
108. Kelly DA, Piasecki C, Anthony A, Dhillon AP, Pounder RE, Wakefield AJ. Focal reduction of villous blood flow in early indomethacin enteropathy: a dynamic vascular study in the rat. Gut 1998;42:366-373.
109. Ross DS, Roy TR. Potentiation of rat colon intraepithelial lymphocyte (IEL) natural killer (NK) activity with indomethacin. Adv Exp Med Biol 1987;216A:527-531.
110. Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 2014;40:16-23.
111. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012;87:732-738.
112. Greywoode R, Braunstein ED, Arguelles-Grande C, Green PH, Lebwohl B. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study. Mayo Clin Proc 2014;89:1239-1243.
113. Marietta EV, Nadeau AM, Cartee AK, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther 2015;42:1303-1314.
114. Ruskone-Fourmestraux A, Delmer A, Hennequin C. Gastrointestinal lymphomas. Gastroenterol Clin Biol 2006;30 Spec No 2:2S81-2S90.
115. Ruskoné-Fourmestraux A, Audouin J. Primary gastrointestinal tract mantle cell lymphoma as multiple lymphomatous polyposis. Best Pract Res Clin Gastroenterol 2010;24:35-42.
116. Daum S, Thiel E, Zeitz M. Is intestinal diffuse large B cell lymphoma a relatively benign disease? Leuk Res 2007;31:287-289.
117. Iwamuro M, Kondo E, Takata K, Yoshino T, Okada H. Diagnosis of follicular lymphoma of the gastrointestinal tract: A better initial diagnostic workup. World J Gastroenterol 2016;22:1674-1683.
118. Ondrejka S, Jagadeesh D. Enteropathy-associated T-cell lymphoma. Curr Hematol Malig Rep 2016;11:504-513.
119. Rishi AR, Rubio-Tapia A, Murray JA. Refractory celiac disease. Expert Rev Gastroenterol Hepatol 2016;10:537-546.
120. Woodman I, Schofield JB, Haboubi N. The histopathological mimics of inflammatory bowel disease: a critical appraisal. Tech Coloproctol 2015;19:717-727.
121. Peled JU, Hanash AM, Jenq RR. Role of the intestinal mucosa in acute gastrointestinal GVHD. Blood 2016;128:2395-2402.
122. Washington K, Jagasia M. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum Pathol 2009;40:909-917.
123. De Giorgio R, Barbara G, Stanghellini V, et al. Diagnosis and therapy of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(Suppl 2):10-22.
124. De Giorgio R, Barbara G. Is irritable bowel syndrome an inflammatory disorder? Curr Gastroenterol Rep 2008;10:385-390.
125. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
126. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-811.
127. Sundin J, Rangel I, Kumawat AK, Hultgren-Hörnquist E, Brummer RJ. Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients. Scand J Gastroenterol 2014;49:1068-1075.
128. Aziz I, Evans KE, Hopper AD, Smillie DM, Sanders DS. A prospective study into the aetiology of lymphocytic duodenosis. Aliment Pharmacol Ther 2010;32:1392-1397.
129. Remes-Troche JM, Adames K, Castillo-Rodal AI, et al. Intraepithelial gammadelta+ lymphocytes: a comparative study between celiac disease, small intestinal bacterial overgrowth, and irritable bowel syndrome. J Clin Gastroenterol 2007;41:671-676.
130. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009;29:765-773.
131. Hammer STG, Maneerattanaporn M, Rude K, et al. Duodenal lymphocytosis with normal villous architecture: How often is it celiac disease? Mod Pathol 2010;23(Suppl 1):146A.
132. Losurdo G, Piscitelli D, Giangaspero A, et al. Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up. World J Gastroenterol 2015;21:7545-7552.
133. Singh P, Lauwers GY, Garber JJ. Outcomes of seropositive patients with Marsh 1 histology in clinical practice. J Clin Gastroenterol 2016;50:619-623.
134. Aziz I, Key T, Goodwin JG, Sanders DS. Predictors for celiac disease in adult cases of duodenal intraepithelial lymphocytosis. J Clin Gastroenterol 2015;49:477-482.
135. Losurdo G, Giorgio F, Piscitelli D, et al. May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis? World J Gastroenterol 2016;22:8017-8025.
136. Brar P, Kwon GY, Egbuna II, et al. Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease. Dig Liver Dis 2007;39:26-29.
137. Ludvigsson JF, Bai JC, Biagi F, et al; British Society of Gastroenterology. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut 2014;63:1210-1228.
138. Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol 2008;103:190-195.
139. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment:A matter of geography? World J Gastroenterol 2013;19:8168-8180.
140. Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/ Florence Consensus Report. Gut 2017;66:6-30.
141. Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. Expert Opin Pharmacother 2007;8:1885-1902.
142. Gatta L, Scarpignato C. Systematic review with meta-analysis:rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017;45:604-616.
143. DuPont HL. Persistent diarrhea: a clinical review. JAMA 2016;315:2712-2723.
144. Marietta EV, Cartee A, Rishi A, Murray JA. Drug-induced enteropathy. Dig Dis 2015;33:215-220.
145. Nowak-Wegrzyn A, Szajewska H, Lack G. Food allergy and the gut. Nat Rev Gastroenterol Hepatol 2017;14:241-257.
146. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
147. Dignass A, Van Assche G, Lindsay JO, et al; European Crohn’s and Colitis Organisation (ECCO). The second European evidencebased Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010;4:28-62.
148. Guandalini S, Cernat E, Moscoso D. Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children. Benef Microbes 2015;6:209-217.
149. Laterza L, Ianiro G, Scoleri I, et al. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2015;16:607-615.
150. Scarpellini E, Laterza L, Ianiro G, Tack J, Abenavoli L, Gasbarrini A. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2016;17:1395-1402.
151. Nagarajan N, Morden A, Bischof D, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2015;27:1002-1010.
152. Sainsbury A, Ford AC. Treatment of irritable bowel syndrome:beyond fiber and antispasmodic agents. Therap Adv Gastroenterol 2011;4:115-127.
153. Shah SL, Lacy BE. Dietary interventions and irritable bowel syndrome: a review of the evidence. Curr Gastroenterol Rep 2016;18:41.
154. Lacy BE, Levenick JM, Crowell MD. Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2012;8:653-660.
155. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016 Feb 19. doi: 10.1053/j.gastro.2016.02.032. [Epub ahead of print].